Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia.

acute lymphoblastic leukemia chemoresistance microenvironment thiopurine compounds tissue culture media

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 29 05 2024
accepted: 03 07 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 5 8 2024
Statut: epublish

Résumé

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with relapse being a major obstacle to successful treatment. Our understanding of the mechanisms driving chemotherapy resistance and ultimately relapse in leukemia remains incomplete. Herein, we investigate the impact of the tumor microenvironment on leukemia cell drug responses using human plasma-like media (HPLM), designed to mimic physiological conditions more accurately

Identifiants

pubmed: 39099696
doi: 10.3389/fonc.2024.1440650
pmc: PMC11294174
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1440650

Informations de copyright

Copyright © 2024 Wang, Ostergaard, Kang, Sagong, Twite, Vargas-Morales and Gordon.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Xiaohong Wang (X)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Jason Ostergaard (J)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Jongseok Kang (J)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Grace Sagong (G)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Rachel Twite (R)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Andrea Vargas-Morales (A)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Peter M Gordon (PM)

Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Classifications MeSH